# A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

> **NCT06357377** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Neonc Technologies, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Pediatric Tumor of CNS
- Pediatric Tumor of Brain
- Diffuse Midline Glioma, H3 K27M-Mutant
- Pediatric Tumor of Brain Stem
- Pineocytoma
- Choroid Plexus Carcinoma, Childhood
- Spinal Cord Tumor
- High Grade Glioma

## Interventions

- **DRUG:** NEO100

## Key facts

- **NCT ID:** NCT06357377
- **Lead sponsor:** Neonc Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06357377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06357377, "A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06357377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*